Anzeige
Mehr »
Login
Samstag, 01.04.2023 Börsentäglich über 12.000 News von 687 internationalen Medien
Hot Stock des Tages! Warum diese Aktie ein 1.000%-er sein könnte!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1XDTV ISIN: NL0010696654 Ticker-Symbol: UQ1 
Frankfurt
31.03.23
09:32 Uhr
17,920 Euro
-0,510
-2,77 %
1-Jahres-Chart
UNIQURE NV Chart 1 Jahr
5-Tage-Chart
UNIQURE NV 5-Tage-Chart
RealtimeGeldBriefZeit
18,27018,89031.03.
18,29518,85531.03.

Aktuelle News zur UNIQURE Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
13.03.uniQure Inc.: uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)187LEXINGTON, Mass. and AMSTERDAM, the Netherlands, March 13, 2023(NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced...
► Artikel lesen
07.03.Analyst Ratings for uniQure4
02.03.uniQure Inc.: uniQure to Participate in Multiple Upcoming Industry Conferences in March281LEXINGTON, Mass. and AMSTERDAM, the Netherlands, March 02, 2023N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced...
► Artikel lesen
UNIQURE Aktie jetzt für 0€ handeln
28.02.uniQure Stock Trying To Close In On Key Technical Measure5
28.02.uniQure To Rally Around 162%? Here Are 10 Other Analyst Forecasts For Tuesday4
27.02.uniQure N.V. - 8-K, Current Report1
27.02.uniQure N.V. - S-8, Securities to be offered to employees in employee benefit plans1
27.02.uniQure GAAP EPS of -$2.71 beats by $0.98, revenue of $106.48M beats by $83.27M2
27.02.uniQure N.V. - 10-K, Annual Report1
27.02.uniQure Inc.: uniQure Announces 2022 Financial Results and Highlights Recent Company Progress450~ Achieved U.S. and European Commission marketing approvals of first and only gene therapyfor adults with hemophilia B ~ ~ Advancing development of AMT-130 for patients with Huntington's disease...
► Artikel lesen
23.02.uniQure Inc.: uniQure Announces HOPE-B Clinical Trial Data Published in the New England Journal of Medicine, Demonstrating Durability and Other Benefits of HEMGENIX® (etranacogene dezaparvovec-drlb)328~ Data follow the historic approval of the first gene therapy for hemophilia B, which has been shown in clinical trials to reduce the rate of annual bleeds, reduce or eliminate the need for prophylactic...
► Artikel lesen
21.02.uniQure N.V. - 8-K, Current Report1
21.02.uniQure Inc.: uniQure announces the European Commission approval of the first gene therapy for adults with hemophilia B362~ Historic approval represents the first gene therapy in Europe to treat hemophilia B and provides a new treatment option for patients that reduces the rate of annual bleeds, reduces or eliminates the...
► Artikel lesen
31.01.UniQure In-Licenses Early-Stage Amyotrophic Lateral Sclerosis Candidate, Analyst Says Deal Compliments Its Pipeline4
31.01.After snagging most expensive drug title, uniQure doles out $10M upfront for ALS prospect2
31.01.UniQure cashes out $10M upfront to get candidate for inherited ALS2
31.01.uniQure inks licensing deal for gene therapy candidate targeting ALS3
31.01.uniQure Inc.: uniQure and Apic Bio enter into global licensing agreement for APB-102, a clinical stage gene therapy for patients with ALS caused by mutations in SOD1588~ License of APB-102 further strengthens uniQure's pipeline of innovative gene therapies to treat neurological disorders and miRNA-based gene silencing programs ~ ~ APB-102 and uniQure's c9orf72-ALS...
► Artikel lesen
20.12.22uniQure Inc.: uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)284LEXINGTON, Mass. and AMSTERDAM, Dec. 20, 2022(NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the Company...
► Artikel lesen
16.12.22uniQure N.V. - 8-K, Current Report2
Seite:  Weiter >>
56 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1